The Latest SPAC News and Rumors: August 22, 2022

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Rumble launches beta version of ad platform, and ZyVersa demonstrates effectiveness of inflammsome

Rumble Launches Beta Version of Ad Platform

Today, the video-sharing platform Rumble announced the launch of the beta version of Rumble Ads, which will be open to all verified businesses.

The beta version of the new platform will allow advertisers to access a portion of the user traffic on Rumble’s website, create campaigns, view analytics, and much more. The platform will be launched initially for display advertisements, with video and native advertisements to follow in the next quarter. The platform also supports the ability for Publishers to access advertiser demand. Select Publishers will be granted access to the Beta version of the platform this quarter.

The company announced in December 2021 the execution of a definitive business combination agreement with CF Acquisition Corp. VI (NASDAQ: CFVI).

READ

Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa’s Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR), a blank-check special purpose acquisition company, are pleased to announce that data published in Frontiers in Molecular Neuroscience demonstrate that ZyVersa’s inflammasome ASC inhibitor, IC 100, is effective in reducing inflammation in the brains of aged mice.

Age-related chronic inflammation is implicated in development and progression of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. The research was conducted by renowned scientists from the University of MiamiMiller School of Medicine, Dr. Juan Pablo de Rivero Vaccari and Dr. Robert W. Keane.